All data are based on the daily closing price as of October 24, 2025
a
Alar Pharmaceuticals
6785.TWO
8.80 USD
-0.61
-6.48%
Overview
Last close
8.80 usd
Market cap
587.68M usd
52 week high
9.63 usd
52 week low
3.40 usd
Target price
9.41 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
2560.5093
Price/Book Value
7.6951
Enterprise Value
534.55M usd
EV/Revenue
2330.9955
EV/EBITDA
413.1064
Key financials
Revenue TTM
229322.09 usd
Gross Profit TTM
152221.86 usd
EBITDA TTM
-2.66M usd
Earnings per Share
-0.01 usd
Dividend
0.01 usd
Total assets
78.46M usd
Net debt
-20.81M usd
About
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.